← Leaderboards
Rebecca Sara Cook
Vanderbilt University
$4,266,124
Attributed
$8,216,623
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,216,623 · 6
By mechanism
R01$7,048,172 · 3
P50$1,168,451 · 3
Top collaborators
- Craig Lewis Duvall15 shared
- Dana M Brantley-Sieders9 shared
- Md Jashim Uddin7 shared
- Kasey C Vickers7 shared
Most similar at Vanderbilt University
Same institution · by research overlap
- Md Jashim Uddin$728,003
- Satoru Eguchi$8,928,684
- Brent N Rexer$1,140,154
- Thomas A Werfel$1,074,749
- Benjamin Christian Hacker$78,323
Others in their field
Top investigators on “Malignant Breast Neoplasm”
- David Heimbrook · Leidos Biomedical Research, Inc.$347,312,063
- Norman Wolmark · Nsabp Foundation, Inc.$122,067,540
- Walter John Curran · Thomas Jefferson University$97,002,422
- Monica M Bertagnolli · Strang Cancer Prevention Center$84,975,759
- Joseph P. Costantino · University Of Pittsburgh At Pittsburgh$68,847,428
- Jan C Buckner · Mayo Clinic Coll Of Medicine, Rochester$60,763,376
Research focus
Malignant Breast NeoplasmIn VivoTumorCellsPharmaceutical PreparationsBreast Cancer ModelTriple-Negative Invasive Breast CarcinomaBiologicalMalignant NeoplasmsChemotherapyInvestigationPathway InteractionsDrug KineticsXenograft ProcedureRna InterferenceCancer SubtypesDesignSignal TransductionCell SurvivalMammary NeoplasmsNeoplastic CellInvestigational TherapiesBreast Cancer PatientMolecular Target
Grant awards (26)
In Situ Albumin Binding siRNAs for Triple Negative Breast Cancer Tumor Penetration and Molecularly Targeted Therapy$550,518
R01 · FY2025 · CA
In Situ Albumin Binding siRNAs for Triple Negative Breast Cancer Tumor Penetration and Molecularly Targeted Therapy$522,993
R01 · FY2024 · CA
In Situ Albumin Binding siRNAs for Triple Negative Breast Cancer Tumor Penetration and Molecularly Targeted Therapy$555,637
R01 · FY2023 · CA
In Situ Albumin Binding siRNAs for Triple Negative Breast Cancer Tumor Penetration and Molecularly Targeted Therapy$117,567
R01 · FY2023 · CA
In Situ Albumin Binding siRNAs for Triple Negative Breast Cancer Tumor Penetration and Molecularly Targeted Therapy$553,948
R01 · FY2022 · CA
NextGen RNAi Delivery to Breast Tumors for Selective mTORC2 Blockade$441,312
R01 · FY2022 · CA
In Situ Albumin Binding siRNAs for Triple Negative Breast Cancer Tumor Penetration and Molecularly Targeted Therapy$117,567
R01 · FY2022 · CA
NextGen RNAi Delivery to Breast Tumors for Selective mTORC2 Blockade$72,819
R01 · FY2022 · CA
In Situ Albumin Binding siRNAs for Triple Negative Breast Cancer Tumor Penetration and Molecularly Targeted Therapy$617,228
R01 · FY2021 · CA
NextGen RNAi Delivery to Breast Tumors for Selective mTORC2 Blockade$450,319
R01 · FY2021 · CA
NextGen RNAi Delivery to Breast Tumors for Selective mTORC2 Blockade$74,306
R01 · FY2021 · CA
NextGen RNAi Delivery to Breast Tumors for Selective mTORC2 Blockade$450,319
R01 · FY2020 · CA
NextGen RNAi Delivery to Breast Tumors for Selective mTORC2 Blockade$74,113
R01 · FY2020 · CA
NextGen RNAi Delivery to Breast Tumors for Selective mTORC2 Blockade$436,809
R01 · FY2019 · CA
NextGen RNAi Delivery to Breast Tumors for Selective mTORC2 Blockade$464,569
R01 · FY2018 · CA
McI-1 Inhibitors for the treatment of Breast Cancer$192,749
P50 · FY2017 · CA · contact PI
McI-1 Inhibitors for the treatment of Breast Cancer$192,269
P50 · FY2016 · CA · contact PI
McI-1 Inhibitors for the treatment of Breast Cancer$209,904
P50 · FY2015 · CA · contact PI
McI-1 Inhibitors for the treatment of Breast Cancer$101,898
P50 · FY2015 · CA · contact PI
McI-1 Inhibitors for the treatment of Breast Cancer$318,023
P50 · FY2014 · CA · contact PI
HER3 Signaling in Development and Cancer of the Breast$304,570
R01 · FY2014 · CA · contact PI
HER3 Signaling in Development and Cancer of the Breast$295,150
R01 · FY2013 · CA · contact PI
McI-1 Inhibitors for the treatment of Breast Cancer$153,608
P50 · FY2013 · CA · contact PI
HER3 Signaling in Development and Cancer of the Breast$313,989
R01 · FY2012 · CA · contact PI
HER3 Signaling in Development and Cancer of the Breast$312,814
R01 · FY2011 · CA · contact PI
HER3 Signaling in Development and Cancer of the Breast$321,625
R01 · FY2010 · CA · contact PI